GMED Stock Recent News
GMED LATEST HEADLINES
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w.
Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains.
GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects.
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
GMED announces the commercial launch of COHERE ALIF Spacer and Modulus ALIF Blades.
AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced two commercial launches: COHERE™ ALIF Spacer: The first Porous PEEK™ interbody spacer for anterior lumbar interbody fusion (ALIF) surgery, and Modulus™ ALIF Blades: An extension of the market-leading Modulus™ ALIF interbody spacer system.
AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in San Diego, Calif., from March 10-14, 2025.
AUDUBON, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego.
Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately.
REDWOOD CITY, Calif. , March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results.